Dr. Griguer obtained B.S. (Cellular and Molecular Biology), M.Sc. (Embryology and Cellular Development) and Ph.D. (Neurobiology and Cellular and Molecular Biology) degrees at the University of Montpellier (France), in 1993. Following postdoctoral fellowships at the University of Colorado Medical Center and University of Washington, she worked in biotechnologies from 1999 to 2002. In 2005, she was appointed to the Department of Surgery as Instructor and in 2008, as Assistant Professor. Dr. Griguer's research interests center on bioenergetics pathways involved in the development and progression of malignant glioma, and translating findings from "benchtop" to bedside. Two main topics are studied in her laboratory: the role of mitochondrial bioenergetics in chemoresistance and the role of mitochondria in stem cells biology. Her laboratory has developed unique cellular and molecular biological assays applied to mitochondria from human glioma biopsies.
Oliva CR, Nozell SE, Diers A, McClugage SG 3rd, Sarkaria JN, Markert JM, Darley-Usmar VM, Bailey SM, Gillespie GY, Landar A, Griguer CE. (2010) Acquisition of temozolomide chemoresistance in gliomas leads to remodeling of mitochondrial electron transport chain. J Biol Chem. 20870728
Griguer CE,C.R. Oliva,E. Gobin,P. Marcorelles, D.J. Benos, J. R. Lancaster, Jr, G.Y Gillespie. CD133 is a marker of bioenergetic stress in human glioma PLoS ONE. 2008; 3(11): e3655. 18985161
Griguer CE, Oliva CR, Gillespie GY, Gobin E, Marcorelles P. Pharmacologic manipulations of mitochondrial membrane potential (DeltaPsim) selectively in glioma cells. J.Neurooncology, 81, 9-20, (2007) 16862448
Griguer CE, C.R. Oliva, E.E Kelley, G.I. Giles, J.R. Lancaster Jr., G.Y. Gillespie. Xanthine Oxidase-dependent Regulation of Hypoxia-Inducible Factor in Cancer Cells. Cancer Res. 66 (4), 2257-2263 (2006) 16489029
Griguer CE, C.R. Oliva, GY Gillespie. Glucose Metabolism Heterogeneity in Human and Mouse Malignant Glioma Cell Lines. J Neurooncol. 2005 Sep; 74(2):123-33.